Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| mRNA vaccine | 66 | - | - | 0.50 [0.11; 2.28], 2 RCTs, I2=0%
inconclusive result | - | |
| Non replicating viral vector | 34 | - | - | 0.19 [0.06; 0.64], 2 RCTs, I2=0%
moderate degree of certainty | - | |
| first booster dose | 20 | - | - | OBS 0.13 [0.08; 0.24], 6 studies, I2=78%
high degree of certainty | - | |
| Inactivated virus vaccine | 12 | - | - | OBS 0.20 [0.14; 0.28], 1 study, I2=0%
unassessable degree of certainty | - | |
| second booster dose | 7 | - | - | OBS 0.22 [0.17; 0.28], 1 study, I2=0%
unassessable degree of certainty | - | |
| protein subunit vaccine | 4 | - | - | - | - | |
| complete primary vaccine series | 1 | OBS 0.45 [0.34; 0.60], 3 studies, I2=66%
unassessable degree of certainty | - | OBS 0.16 [0.06; 0.41], 5 studies, I2=79%
high degree of certainty | - | |
| heterologous prime-boost | 1 | - | - | - | - | |
| A EFFACER BBV152 (Bharat Biotech, India) | 0 | - | - | - | - | |
| A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725) | 0 | - | - | - | - | |
| A EFFACER_ Vero cell | 0 | - | - | - | - | |
| A EFFACER_sequential Immunization | 0 | - | - | - | - | |
| BCG vaccination | 0 | - | - | - | - | |
| CoVLP (MT-2766, Medicago) | 0 | - | - | - | - | |
| DNA vaccine | 0 | - | - | - | - | |
| ebola vaccine | 0 | - | - | - | - | |
| Replicating Viral Vector | 0 | - | - | - | - | |
| seasonal influenza vaccines | 0 | - | - | - | - | |
| virus-like particles vaccine | 0 | - | - | - | - | |
